Endologix Secures $170 Million Credit Facility with Deerfield Management

Represented Endologix in its $170 million credit facility with Deerfield Management, a leading healthcare investment organization. Under the facility, Deerfield provided Endologix with up to $170 million in funding through a $120 million six-year secured term loan and a $50 million three-year secured asset-based revolving line of credit. 

Endologix develops and manufactures minimally invasive treatments for aortic disorders, with a focus on endovascular stent grafts for the treatment of abdominal aortic aneurysms.